0000000000810969

AUTHOR

S. Tosato

showing 3 related works from this author

Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

2020

The EUGEI project was supported by the European Community’s Seventh Framework Program under grant agreement no. HEALTH-F2-2009-241909 (Project EU-GEI). Dr O’Donovan is supported by MRC programme grant (G08005009) and an MRC Centre grant (MR/ L010305/1). Dr Rutten was funded by a VIDI award number 91718336 from the Netherlands Scientific Organisation. Drs Guloksuz and van Os are supported by the Ophelia research project, ZonMw grant number: 636340001. Dr Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024); CIBERSAM; Madrid Regional Government (B2017/BMD-3740, AGES-CM-2); Fundación Familia Alonso and Fundac…

AdultMaleExposomePsychosisMultifactorial InheritanceEpidemiologyBIRTHSchizotypystructured interviewGENE-ENVIRONMENTPopulationschizotypypopulationEnvironment03 medical and health sciences0302 clinical medicineMedicineHumansSpectrum disorderGenetic Predisposition to DiseasegeneticspsychosiseducationMETAANALYSISvalidationRISKeducation.field_of_studychildhood traumareliabilitybusiness.industryPublic Health Environmental and Occupational HealthAbsolute risk reductionassociationRegression analysisGenomicsmedicine.disease3. Good health030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaFemaleGene-Environment InteractionSchizophrenic PsychologyOriginal Articlebusiness030217 neurology & neurosurgeryClinical psychologyEpidemiology and Psychiatric Sciences
researchProduct

Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study.

2022

the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI) and FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...)

Schizophrenia/geneticsEnvironmental effects on human beingsRisk factors in diseasesEpidemiologyPsicosipsychosiPathological psychologyGenes × environment interactionRisk FactorsSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.psychosocial stressorsHumanspsychosisPsychotic Disorders/geneticsSettore MED/25 - PsichiatriaInfluència del medi ambient en l'homeGenètica de la conductaFactors de risc en les malaltiesGenes × environment interactionsPublic Health Environmental and Occupational HealthPsychosespolygenic risk score for schizophreniaPsicopatologiaPsychiatry and Mental healthPsychotic DisordersBehavior geneticsSchizophreniaEsquizofrèniaGene-Environment Interaction
researchProduct

Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use

2020

Abstract Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic p…

MalecognitionIntelligenceComorbiditySUBSTANCE USE DISORDERS0302 clinical medicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.MedicinePREDICTORSRISKeducationeducation.field_of_studybiologyCognitionMiddle AgedPsychosocial FunctioningsociabilityPsychiatry and Mental healthSchizophreniaFemaleMarijuana UseSocial AdjustmentMENTAL-HEALTHAdultmedicine.medical_specialtyPsychosisAdolescentPopulation1ST EPISODEDRUG-USEpreillnessSettore MED/01 - Statistica MedicaYoung Adult03 medical and health sciencesAGESettore M-PSI/08 - Psicologia ClinicaHumansCognitive skilleducationPsychiatrySettore MED/25 - Psichiatriabusiness.industryCase-control studypreillnebiology.organism_classificationmedicine.diseaseEDUCAÇÃO030227 psychiatryschizophreniaPsychotic DisordersCase-Control StudiesONSETCannabisNEUROCOGNITIONbusinessmarijuanaNeurocognitive030217 neurology & neurosurgeryRegular ArticlesSchizophrenia Bulletin
researchProduct